Clinical Trial Update: A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a combination of nivolumab with FOLFOX and regorafenib in HER2-negative esophagogastric cancer; the study is currently active but not r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophagogastric Cancer

Drugs mentioned

• FOLFOX regimen (folinic acid (leucovorin) + fluorouracil + oxaliplatin)
• Regorafenib (regorafenib)
• nivolumab (nivolumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Esophagogastric Cancer, HER2-Negative | Phase 2 | Status: ACTIVE_NOT_RECRUITING